Intervention

Radium-223 dichloride (Xofigo, BAY88-8223)

ClinicalTrials.gov intervention label

Clinical trials21

Recruiting0

Common conditions10

Lead sponsors shown1

Clinical trials

21 shown

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone LevelsNCT05301062 · 2022-09-15

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the BonesNCT04521361 · 2020-11-16

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)NCT04597125 · 2020-11-09

ACTIVE_NOT_RECRUITING

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)NCT04516161 · 2020-08-03

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the BoneNCT04232761 · 2020-07-07

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the BodyNCT04281147 · 2020-02-24

PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEnNCT04256993 · 2020-02-15

Treatment Satisfaction With Ra-223 in JapanNCT03315260 · 2019-04-11

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare PopulationNCT02518698 · 2015-08-31

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerNCT02258451 · 2015-06-04

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast CancerNCT02258464 · 2015-03-02

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate CancerNCT02141438 · 2014-08-20

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild SymptomsNCT02043678 · 2014-03-30

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the BoneNCT02023697 · 2014-03-10

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)NCT02034552 · 2014-03-07

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone MetastasesNCT01934790 · 2013-12-22

Japanese BAY88-8223 Monotherapy Phase II StudyNCT01929655 · 2013-09-30

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone MetastasisNCT01810770 · 2013-03-26

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese PatientsNCT01565746 · 2012-03-01

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)NCT01106352 · 2010-07-01

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesNCT00699751 · 2008-06-12

Common conditions

Prostatic Neoplasms8 Bone Metastases3 Metastatic Castration-resistant Prostate Cancer3 Breast Neoplasms2 Castration-Resistant Prostate Cancer2 Prostate Cancer2 Bone Metastatic Castration-resistant Prostate Cancer1 Hormone Refractory Prostate Cancer1 Metastatic Castrate Resistant Prostate Cancer (mCRPC)1 Metastatic Castration Resistant Prostate Cancer (mCRPC)1

Leading sponsors

Trial status mix

COMPLETED18

TERMINATED2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE27

PHASE14

PHASE33

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.